Synthesis and Antimicrobial Studies of Selenadiazolo Benzimidazoles

Design, synthesis and biological evaluation of novel deoxyvasicinone-indole as multi-target agents for Alzheimer's disease

In this study, a series of multifunctional hybrids (6a-6l) against Alzheimer's disease were designed and obtained by conjugating the pharmacophores of deoxyvasicinone and indole. These analogs of deoxyvasicinone-indole were evaluated as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), and as inhibitors of amyloid aggregation (Aβ_1-42) for treatment of Alzheimer's disease (AD). Subsequently, AChE induced Aβ aggregation inhibition test was also performed for selected compounds. Biological activity results demonstrated that compound 6b was the most potent and balanced dual ChEs inhibitor with IC₅₀ values 0.12 µM and 0.15 µM for eeAChE and eqBuChE, respectively. Kinetic analysis and docking study indicated that compound 6b was a mixed-type inhibitor for both AChE and BuChE. Compound 6b also found to be the best inhibitors of self-induced Aβ_1-42 aggregation with IC₅₀ values of 1.21 µM. Compound 6b also afforded excellent inhibition of AChE-induced Aβ_1-42 aggregation by 81.1%. Overall, these results indicate that 6b may be considered as lead compound for the development of highly effective anti-AD drugs.

I2/DMSO-catalyzed one-pot approach for the synthesis of 1,3,4-selenadiazoles

A three-component cascade reaction for the synthesis of 1,3,4-selenadiazoles and their derivatives from arylaldehydes, hydrazine, and elemental selenium by using molecular iodine is reported. This strategy is operationally simple, well-suited to a wide range of functional groups, and provides the desired products in moderate to excellent yields. The proposed mechanism predicts that the reaction tolerated a radical process.